Published in:
01-08-2017 | Guidelines
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
Authors:
Murat Fani Bozkurt, Irene Virgolini, Sona Balogova, Mohsen Beheshti, Domenico Rubello, Clemens Decristoforo, Valentina Ambrosini, Andreas Kjaer, Roberto Delgado-Bolton, Jolanta Kunikowska, Wim J. G. Oyen, Arturo Chiti, Francesco Giammarile, Stefano Fanti
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 9/2017
Login to get access
Abstract
Purpose & Methods
Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.
Results & Conclusion
The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.